Agios Pharma (AGIO) Misses Q3 EPS by 1c

Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.81), $0.01 worse than the analyst estimate of ($1.80). Revenue for the quarter came in at $26 million versus the consensus estimate of $35.15 million.

“The third quarter was marked by strong commercial execution, now a full year since the U.S. launch of TIBSOVO®, and several meaningful clinical updates spanning our early and late stage oncology programs that advance our strategy,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “As we look ahead to the remainder of 2019, we are focused on achieving our remaining key milestones, including completing enrollment in our mitapivat PK deficiency pivotal program, establishing proof of concept for mitavipat in thalassemia, initiating our pivotal trial of vorasidenib in low-grade glioma and submission of the TIBSOVO® supplemental new drug application for IDH1 mutant cholangiocarcinoma. These milestones are critical steps toward realizing the value-creation potential for both our oncology and rare genetic disease portfolios in 2020 and beyond.”

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance